AAM
EBS icon

Advisors Asset Management’s Emergent Biosolutions EBS Stock Holding History

Advisors Asset Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,493
Closed -$5.08K – 1411
2023
Q3 		$5.08K Sell
1,493
-325
-18% -$1.8K ﹤0.01% 1397
2023
Q2 		$13.4K Sell
1,818
-1,742
-49% -$16.2K ﹤0.01% 1392
2023
Q1 		$36.9K Sell
3,560
-156
-4% -$1.89K ﹤0.01% 1336
2022
Q4 		$43.9K Sell
3,716
-2,810
-43% -$43.5K ﹤0.01% 1352
2022
Q3 		$137K Sell
6,526
-199
-3% -$5.54K ﹤0.01% 1210
2022
Q2 		$209K Sell
6,725
-2,479
-27% -$84.6K ﹤0.01% 1155
2022
Q1 		$378K Sell
9,204
-430
-4% -$19K 0.01% 1082
2021
Q4 		$419K Buy
9,634
+975
+11% +$44.1K 0.01% 1055
2021
Q3 		$434K Buy
8,659
+681
+9% +$41.2K 0.01% 1057
2021
Q2 		$503K Buy
7,978
+1,072
+16% +$68.9K 0.01% 1000
2021
Q1 		$642K Buy
6,906
+1,498
+28% +$153K 0.01% 956
2020
Q4 		$485K Buy
5,408
+2,687
+99% +$247K 0.01% 977
2020
Q3 		$281K Buy
2,721
+1,350
+98% +$146K 0.01% 1083
2020
Q2 		$108K Buy
1,371
+1,309
+2,111% +$97.5K ﹤0.01% 1287
2020
Q1 		$4K Sell
62
-208
-77% -$12K ﹤0.01% 1449
2019
Q4 		$15K Sell
270
-10
-4% -$542 ﹤0.01% 1479
2019
Q3 		$15K Sell
280
-2
-0.7% -$93 ﹤0.01% 1496
2019
Q2 		$14K Buy
282
+15
+6% +$719 ﹤0.01% 1481
2019
Q1 		$13K Buy
267
+174
+187% +$10.3K ﹤0.01% 1736
2018
Q4 		$6K Buy
+93
New +$6K ﹤0.01% 1540
2017
Q1 		– Sell
-7,464
Closed -$245K – 1611
2016
Q4 		$245K Sell
7,464
-108
-1% -$3.24K ﹤0.01% 1336
2016
Q3 		$239K Sell
7,572
-9
-0.1% -$262 ﹤0.01% 1315
2016
Q2 		$213K Sell
7,581
-186
-2% -$7.29K ﹤0.01% 1335
2016
Q1 		$282K Buy
7,767
+1,738
+29% +$61.4K ﹤0.01% 1238
2015
Q4 		$241K Buy
+6,029
New +$210K ﹤0.01% 1344

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advisors Asset Management's EBS Position: Q4 2023 in Review

Advisors Asset Management sold out of Emergent Biosolutions (EBS) in Q4 2023, closing a stake of 1,493 shares — an estimated $5.08K sold.

Advisors Asset Management first reported a position in EBS in Q4 2015 and held it in 25 quarters. The position peaked at $642K in Q1 2021. 134 funds tracked by Wall St. Rank hold EBS as of Q4 2023.

  • Advisors Asset Management reported no remaining Emergent Biosolutions position as of Q4 2023 after selling out during the quarter.
  • Advisors Asset Management sold 1,493 Emergent Biosolutions shares in Q4 2023, an estimated $5.08K.
  • Advisors Asset Management first reported a position in Emergent Biosolutions in Q4 2015 and held it in 25 quarters.
  • Advisors Asset Management's Emergent Biosolutions position peaked at $642K in Q1 2021.
  • 134 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2023.

Based on Advisors Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.